Epithelial ovarian cancer: A case report

Gao,Jianyuan; Fang,Haiying; Wang,Xiaoming; Wu,Liping; Zhang,Ronghuai; Han,Yajun

doi:10.3892/etm.2014.1970

November-2014 Volume 8 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2014 Volume 8 Issue 5

Full Size Image

Case Report

Epithelial ovarian cancer: A case report

Authors:
- Jianyuan Gao
- Haiying Fang
- Xiaoming Wang
- Liping Wu
- Ronghuai Zhang
- Yajun Han
View Affiliations / Copyright

Affiliations: Department of the VIP Ward, The First Affiliated Hospital, The Fourth Military Medical University of the PLA, Xi'an, Shaanxi 710032, P.R. China
Pages: 1535-1538
|
Published online on: September 17, 2014

https://doi.org/10.3892/etm.2014.1970
Expand metrics +

Abstract

An 82‑year‑old female was diagnosed with ovarian cancer in May 2004. Following gynecological surgery, pathological evaluation showed stage IIIC epithelial ovarian cancer. From June 2004 to January 2005, the patient received six cycles of conventional treatment combined with intravenous paclitaxel (Taxol®) and cisplatin. The patient developed abdominal distension and experienced a gradual deterioration in health during 2007, with admission to The First Affiliated Hospital in May 2007. The patient presented with severe abdominal distension and breathing difficulty on May 15 and appeared to be in critical condition. Ultrasound examination revealed massive ascites and left‑side pleural effusion. Thoracentesis and abdominocentesis were performed, and 300 mg carboplatin was administered intraperitoneally on May 19, followed by a second abdominocentesis on May 21. However, these treatments did not alleviate the symptoms, and 200 mg bevacizumab was administered by intravenous infusion on May 27. The condition of the patient gradually improved and 400 mg bevacizumab was administered by intravenous infusion every two weeks from June 9. From December, the dosage of bevacizumab was reduced to 200 mg every two weeks. In addition, 300 mg carboplatin was administered intraperitoneally on November 4 and intraperitoneal carboplatin chemotherapy was repeated thereafter. The patient exhibited disease‑free survival until July 2009, at which time disease progression was observed and the cancer recurred in August 2009. The patient died of multiple organ failure in September 2009. Bevacizumab rapidly eliminated the patient's massive ascites and pleural effusion, and achieved an effect that was not possible with other treatments. Therefore, bevacizumab is an effective therapy for late‑stage relapse and refractory ovarian cancer.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Morgan RJ Jr, Alvarez RD, Armstrong DK, et al: Epithelial Ovarian Cancer Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 9:82–113. 2011.
3	Willmott LJ and Fruehauf JP: Targeted therapy in ovarian cancer. J Oncol. 2010:7404722010. View Article : Google Scholar : PubMed/NCBI
4	Armstrong DK, Bundy B, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
5	Burger RA, Brady MF, Bookman MA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol (ASCO Meeting Abstracts). 28:LBA12010.
6	Barbera L, Elit L, Krzyzanowska M, Saskin R and Bierman AS: End of life care for women with gynecologic cancers. Gynecol Oncol. 118:196–201. 2010. View Article : Google Scholar : PubMed/NCBI
7	Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 102:425–428. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 111:530–532. 2008. View Article : Google Scholar : PubMed/NCBI
9	Woopen H and Sehouli J: Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 29:3353–3359. 2009.PubMed/NCBI
10	Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer. 107:83–89. 2006. View Article : Google Scholar
11	Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 25:5165–5171. 2007. View Article : Google Scholar : PubMed/NCBI
12	Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
13	Strauss HG, Henze A, Teichmann A, et al: Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol. 104:612–616. 2007. View Article : Google Scholar : PubMed/NCBI
14	Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 24:4699–4707. 2006. View Article : Google Scholar : PubMed/NCBI
15	Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 28:3323–3329. 2010. View Article : Google Scholar : PubMed/NCBI
16	Rose PG, Blessing JA, Mayer AR and Homesley HD: Prolonged oral etoposide as second- line therapy for platinum- resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 16:405–410. 1998.PubMed/NCBI
17	Emons G and Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod. 9:1364–1379. 1994.PubMed/NCBI
18	Wiernik PH, Greenwald ES, Ball H, Young JA and Vogl S: High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884. Am J Clin Oncol. 21:565–567. 1998. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Epithelial ovarian cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Related Articles